Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis

Anastasios Panagopoulos, Saurabhi Samant, Jules Joel Bakhos, Martin Liu, Behram Khan, Janaki Makadia, Fayaz Muhammad, Forrest M. Kievit, Devendra K. Agrawal, Yiannis S. Chatzizisis

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Triggering receptor expressed on myeloid cells-1 (TREM-1) is a transmembrane protein expressed on endothelial cells, white blood cells, smooth muscle cells and platelets. TREM-1 plays an important role in innate immunity. TREM-1 activation pathways are implicated both in sepsis and in non-infectious inflammatory conditions, including atherosclerosis. TREM-1 enhances the subendothelial lipid accumulation and expression of pro-inflammatory cytokines and matrix-degrading enzymes, thereby promoting inflammation and plaque destabilization. TREM-1 inhibitors attenuate the inflammatory process in the atherosclerotic plaque, leading to plaque stabilization. This review focuses on the role of TREM-1 in the pathophysiology of atherosclerosis and the effects of TREM-1 inhibition in the natural history of the disease.

Original languageEnglish (US)
Article number108182
JournalPharmacology and Therapeutics
StatePublished - Oct 2022


  • Atherosclerosis
  • Inflammation
  • Inhibitors
  • TREM-1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis'. Together they form a unique fingerprint.

Cite this